Difference between revisions of "Resource:69dad1bb-9632-43ed-b3c1-c49a1fcd8910"
From The Embassy of Good Science
Marc.VanHoof (talk | contribs) |
Marc.VanHoof (talk | contribs) |
||
| Line 1: | Line 1: | ||
{{Resource | {{Resource | ||
|Resource Type=Cases | |Resource Type=Cases | ||
| − | |Title=In the | + | |Title=In the Grip of the Python: Conflicts at the university-industry interface |
| − | |Is About=This case is about scientific fraud in research concerning psychopharmacology. Specific it is about the use of the selective serotonin reuptake inhibitor (SSRI) group of antidepressants having the potential to trigger suicidality in a subgroup of patients. | + | |Is About=This case is about scientific fraud in research concerning psychopharmacology. Specific it is about the use of the selective serotonin reuptake inhibitor (SSRI) group of antidepressants having the potential to trigger suicidality in a subgroup of patients. This is a factual case. |
| − | |||
| − | |||
| − | This is a factual case. | ||
|Important Because=The outcome of such research affects the lives of many patiens who use the SSRI's. | |Important Because=The outcome of such research affects the lives of many patiens who use the SSRI's. | ||
| − | |||
| − | |||
| − | |||
|Important For=Researchers | |Important For=Researchers | ||
}} | }} | ||
| Line 15: | Line 9: | ||
|Has Link=https://link.springer.com/article/10.1007/s11948-003-0020-2 | |Has Link=https://link.springer.com/article/10.1007/s11948-003-0020-2 | ||
}} | }} | ||
| − | {{Related To}} | + | {{Related To |
| + | |Related To Theme=Theme:047c3bec-1747-499b-b6d5-684cbfb81edd;Theme:5f65272f-6e95-4768-8236-bc821a97f3d8 | ||
| + | }} | ||
{{Tags | {{Tags | ||
|Involves=Eli Lilly; Pfizer; University of Toronto | |Involves=Eli Lilly; Pfizer; University of Toronto | ||
Revision as of 18:34, 26 May 2020
ResourcesCases
In the Grip of the Python: Conflicts at the university-industry interface
What is this about?
This case is about scientific fraud in research concerning psychopharmacology. Specific it is about the use of the selective serotonin reuptake inhibitor (SSRI) group of antidepressants having the potential to trigger suicidality in a subgroup of patients. This is a factual case.
Why is this important?
The outcome of such research affects the lives of many patiens who use the SSRI's.
